Alterity Therapeutics Employee Directory

Pharmaceutical ManufacturingVictoria, Australia11-50 Employees

Alterity Therapeutics is a clinical-stage biotechnology company aiming to modify the course of neurodegenerative diseases and improve patient quality of life. Its lead candidate, ATH434, is an oral agent intended to inhibit the aggregation of pathological proteins implicated in neurodegeneration, with preclinical data suggesting it reduces α-synuclein pathology and helps restore normal brain iron balance. The program targets Parkinsonian disorders, including Multiple System Atrophy, and the company maintains offices in Melbourne, Australia and San Francisco, USA.

In addition to ATH434, Alterity operates a broader drug-discovery platform that generates patentable compounds to intervene in disease processes. A recent development noted in 2026 involves positive regulatory feedback from an FDA Type C meeting regarding the planned Phase 3 program for ATH434 in MSA.

Sign up for free to view info

Company overview Email format